ArticleEJNMMI physics2015
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.
Article in EJNMMI physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- PersonalizedEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach.Radiation protection dosimetry · 2026Article
- An international study of factors affecting variability of dosimetry calculations, part 5: impact of segmentation methods.EJNMMI physics · 2026Article
- Evaluation of using small volume of interest regions for clinical kidney dosimetry inEJNMMI physics · 2025Article
- Comparison of tumour segmentation methods for dosimetry in [EJNMMI physics · 2025Article
- Dosimetric implications of kidney anatomical volume changes inEJNMMI physics · 2024Article
- Estimation of kidney doses from [EJNMMI physics · 2024Article
- Anatomy-based correction of kidney PVE on [Formula: see text] SPECT images.EJNMMI physics · 2024Article
- Heterogeneous SSTR2 target expression and a novelFrontiers in oncology · 2024Article
- Tumor dosimetry usingEJNMMI physics · 2023Article
- The effect of long-acting somatostatin analogues on the uptake of [European journal of nuclear medicine and molecular imaging · 2023Article
- Review
- Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody MoleculePharmaceutics · 2022Article
- EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.European journal of nuclear medicine and molecular imaging · 2022Article
- Review
- Practical kidney dosimetry in peptide receptor radionuclide therapy using [EJNMMI physics · 2021Article
- Somatostatin receptor radionuclide therapy in neuroendocrine tumors.Endocrine-related cancer · 2021Review
- Kidney dosimetry in 777 patients duringEJNMMI physics · 2020Article
- Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy.EJNMMI physics · 2020Article
- Comparison of commercial dosimetric software platforms in patients treated withMedical physics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either on anatomical CT (aVOI) or on thresholds on functional images (tVOI). The main aim of the present work was to validate the sVOI in comparison to the other two methods regarding agreement and time efficiency. Secondary aims were to investigate inter-observer variability for the sVOI and the change of functional organ volumes following therapy.
methodsThirty patients diagnosed with neuroendocrine tumours undergoing therapy with (177)Lu-DOTATATE were included. Each patient underwent three SPECT/CT scans at 1, 4 and 7 days after the treatment. Three independent observers calculated absorbed doses to the right and left kidney and the spleen using sVOI and one observer used aVOI. For tVOI, the absorbed doses were calculated based on automatically drawn isocontours around the organs at different thresholds (42, 50, 60 and 70 %). The inter-observer difference between the calculated absorbed doses for sVOI was calculated, and the differences between the three methods were computed. Ratios of organ volumes acquired at days 1, 4 and 7 versus the volume at day 1 were calculated for the tVOI method.
resultsThe differences in results of the absorbed dose calculations using all the sVOI and tVOI were small (<5 %). Absorbed dose calculations using aVOI differed slightly more from these results but were still below 10 %. The differences between the three dose calculation methods varied between <5 and 10 %. The organ volumes derived from the tVOI were independent of time for the spleen while they decreased with time for the kidneys. The fastest analysis was performed with the sVOI method.
conclusionsAll three dose calculation methods rendered comparable results with small inter-observer differences for sVOI. Unlike the spleen, the functional volume of the kidneys decreased over time during therapy, which suggests that the absorbed dose calculation for the kidneys on activity concentrations should be performed for each time point. The sVOI is the preferred method for calculating absorbed doses in solid organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.